Table 1.
Characteristics of subjects with A-grade ACR and Other histopathology
| Total cohort | Training Set | Test Set | |||||||
|---|---|---|---|---|---|---|---|---|---|
| A-grade ACR | Other | p-value | A-grade ACR | Other | p-value | A-grade ACR | Other | p-value | |
| Sex, n (%) | 0.54 | 0.86 | 0.55 | ||||||
| Male | 40 (66%) | 96 (61%) | 30 (65%) | 74 (62%) | 10 (67%) | 22 (56%) | |||
| Female | 21 (34%) | 62 (39%) | 16 (35%) | 45 (38%) | 4 (33%) | 17 (44%) | |||
| Age, mean (SD) | 58.7 (11.0) | 60.1 (11.3) | 0.41 | 59.3 (11.1) | 59.7 (11.4) | 0.85 | 56.9 (10.9) | 61.4 (10.8) | 0.17 |
| Pre-transplant disease, n (%) | 0.80 | 0.93 | 0.28 | ||||||
| Restrictive | 38 (62%) | 92 (58%) | 27 (59%) | 74 (62%) | 11 (73%) | 18 (46%) | |||
| Obstructive | 15 (25%) | 43 (27%) | 12 (26%) | 30 (25%) | 3 (20%) | 13 (33%) | |||
| CF/Bronchiectasis | 2 (3%) | 10 (6%) | 2 (4%) | 5 (4%) | 0 (0%) | 5 (13%) | |||
| Other | 6 (10%) | 13 (8%) | 5 (11%) | 10 (8%) | 1 (7%) | 3 (8%) | |||
| Transplant Type | 0.76 | 0.73 | 1.00 | ||||||
| Bilateral | 34 (56%) | 84 (53%) | 25 (54%) | 61 (51%) | 9 (60%) | 23 (59%) | |||
| Single | 27 (44%) | 74 (47%) | 21 (46%) | 58 (49%) | 6 (40%) | 16 (41%) | |||
| CMV serostatus | 0.41 | 0.55 | 0.78 | ||||||
| R+/D+ | 32 (52%) | 70 (44%) | 24 (52%) | 50 (42%) | 8 (53%) | 20 (51%) | |||
| R+/D− | 14 (23%) | 32 (20%) | 10 (22%) | 24 (20%) | 4 (27%) | 8 (21%) | |||
| R−/D+ | 8 (13%) | 36 (23%) | 7 (15%) | 29 (24%) | 1 (7%) | 7 (18%) | |||
| R−/D− | 7 (12%) | 20 (13%) | 5 (11%) | 16 (13%) | 2 (13%) | 4 (10%) | |||
| Days to Biopsy, mean (SD) | 170 (207) | 230 (253) | 0.10 | 157 (212) | 235 (264) | 0.07 | 213 (194) | 216 (219) | 0.96 |
| Indication for biopsy, n (%) | 0.85 | 1.00 | 1.00 | ||||||
| Surveillance | 49 (80%) | 124 (78%) | 38 (83%) | 97 (82%) | 11 (73%) | 27 (69%) | |||
| For cause | 12 (20%) | 34 (22%) | 8(17%) | 22 (18%) | 4 (27%) | 12 (31%) | |||
| Induction, n (%) | 1.00 | 0.61 | 0.37 | ||||||
| ATG | 32 (52%) | 82 (52%) | 23 (50%) | 65 (55%) | 9 (60%) | 17 (44%) | |||
| Basiliximab | 29 (48%) | 76 (48%) | 23 (50%) | 54 (45%) | 6 (40%) | 22 (56%) | |||
| Tacrolimus trough, mean (SD) | 10.6 (5.4) | 9.9 (3.9) | 0.32 | 10.7 (5.6) | 10.1 (4.1) | 0.46 | 10.5 (4.9) | 9.5 (3.3) | 0.45 |
| FEV1 Percent of baseline, Median (IQR) | 100 (93–100) | 99 (90–100) | 0.06 | 100 (92–100) | 99 (90–100) | 0.13 | 100 (95–100) | 99 (88–100) | 0.23 |
| TBBX histopathology | · | · | · | ||||||
| A1 | 38 (62%) | · | 29 (63%) | · | 9 (60%) | · | |||
| A2 | 17 (28%) | · | 12 (26%) | · | 5 (33%) | · | |||
| A3 | 6 (10%) | · | 5 (11%) | · | 1 (7%) | · | |||
| Lymphocytic Bronchiolitis | 27 (44%) | 70 (44%) | 22 (48%) | 52 (44%) | 5 (33%) | 18 (46%) | |||
| Infection | · | 41 (26%) | · | · | 34 (29%) | · | · | 7 (18%) | |
| Respiratory virus* | · | 10 (6%) | · | 8 (7%) | · | 2 (5%) | |||
| Bacterial** | · | 19 (12%) | · | 18 (15%) | · | 1 (3%) | |||
| Fungal*** | · | 12 (8%) | · | 8 (7%) | · | 4 (10%) | |||
*
3 Coronavirus, 3 parainfluenza, 2 rhinovirus, 1 Respiratory syncytial virus, 1 Influenza A.
**
13 P. aeruginosa, 3 E. coli, 2 H. influenzae, 1 K. pneumonia
***
8 A. fumigatus, 3 A. niger, 1 A. nidulans